LAUSR

Results | We identified 401 interventional prostate cancer clinical trials with an overall survival end point from clinicaltrials .gov (Table). Overall, 47.9% (192) of these trials used sCr alone and/or required participants to have an ANC of 1.5 × 109 cells/L or higher. Specifically, 25.2% (101) of the trials used sCr alone to determine eligibility and 41.4% (166) of the trials required patients to have an ANC of 1.5 × 109 cells/L or higher. The use of sCr alone and/or an ANC cutoff level of 1.5 × 109 cells/L or higher to determine eligibility was more common in trials that were sponsored by academic investigators or cooperative groups vs industry (P < .001), were phase 1 or 2 vs 3 (P < .02), had lower accrual (P < .001), or had at least 1 treatment arm that was considered high toxicity (P < .001) (Table).